R. Toorawa

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

E. Søfteland, U. Broedl, J. Meier, 2016, Diabetes Care.

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study

P. O'Byrne, M. Fležar, K. Beeh, 2015, Respiratory Research.

Dose-Finding Study Of 4-Week, Once-Daily Treatment With Olodaterol, A Novel Long-Acting B2-Agonist, In Patients With Asthma

M. Fležar, K. Beeh, E. Beck, 2012, ATS 2012.

Use of simulation to compare the performance of minimization with stratified blocked randomization

Mark Donovan, Steve Jones, Robert Toorawa, 2009, Pharmaceutical statistics.

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

M. Fležar, C. Laforce, K. Beeh, 2015, Respiratory Research.

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized, double‐blind, placebo‐controlled phase III trial with a 34‐week active‐controlled extension

A. Barnett, S. Patel, H. Woerle, 2012, Diabetes, obesity & metabolism.

Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial

H. Woerle, M. Nauck, Sanjay R. Patel, 2016, Diabetes & vascular disease research.

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

Robert Toorawa, S. Ross, H. Woerle, 2012, Current medical research and opinion.